Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence. - UroToday

-

The purpose of this study was to investigate adherence to recommended adjuvant radiotherapy (aRT) in radical prostatectomy (RP) patients with adverse pathologic features and to analyse the outcome of patients who followed or denied this recommendation.

We included 1140 consecutive RP patients (2006-2015) with non-organ confined (pT3) prostate cancer and either positive surgical margins (R1) and/or lymph node involvement (pN1) and non-detectable postoperative prostate-specific antigen who received multidisciplinary aRT recommendations. Patients were stratified into adherence versus non-adherence to recommendations. Additionally, subgroups within pathologic criteria (pT3R1N0, pT3R0N1, pT3R1N1) were analyzed. Kaplan-Meier, as well as multivariable Cox regression analyses were used to assess biochemical recurrence (BCR)-free survival, metastasis-free survival, cancer-specific survival, and overall survival.

Overall, 508 (44.6%) patients were non-adherent. Of those, 273 (53.6%) did not receive any RT, and 235 (46.4%) received salvage RT. At 8 years, BCR-free survival was 57.7 versus 20.1%, metastasis-free survival was 76.5 versus 75.4%, cancer-specific survival was 91.7 versus 87.4%, and overall survival was 80.4 versus 75.8% in adherent versus non-adherent patients, respectively (P < .001). In multivariable Cox regression predicting BCR, metastatic progression, cancer-specific mortality, and overall mortality, non-adherence to aRT recommendation represented an independent predictor (hazard ratio [HR], 3.8; 95% confidence interval [CI], 3.1-4.5; HR, 1.6; 95% CI, 1.2-2.2; HR, 2.8; 95% CI, 1.5-5.3; and HR, 1.8; 95% CI, 1.2-2.8, respectively).

Only about 55% of patients followed our multidisciplinary recommendations. Adherent patients were significantly less likely to experience BCR, metastatic progression, cancer-specific mortality, and overall mortality. Thus, patients with high risk of recurrence may be advised about the possibility of improved oncologic outcomes in case of adherence to aRT recommendations.

Clinical genitourinary cancer. 2019 Sep 26 [Epub ahead of print]

Sophie Knipper, Maryam Sadat-Khonsari, Katharina Boehm, Philipp Mandel, Lars Budäus, Thomas Steuber, Tobias Maurer, Hans Heinzer, Rudolf Schwarz, Guido Sauter, Derya Tilki, Hartwig Huland, Markus Graefen

Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. Electronic address: ., Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Department of Urology, University Hospital Mainz, Mainz, Germany., Department of Urology, University Hospital Frankfurt, Frankfurt, Germany., Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Department of Radiation Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Department of Pathology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/31648965



https://ift.tt/334HADz

Comments

Post a Comment

Popular posts from this blog

I Wish I Didn't Need an Oncologist at All, But I'm Thankful for the One ...

-
Image
efudex side effects :: Article Creator Inmates Given Ivermectin In Jail Will Each Get $2,000 After Settlement Your browser is not supporteddetroitnews.Com detroitnews.Com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use. Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on detroitnews.Com Efudex Cream Efudex Cream Generic Name & Formulations General Description Fluorouracil 5%. Pharmacological Class Antimetabolite. How Supplied Soln (w. Drop dispenser)—10mL, 25mL; Crm—40g Efudex Cream Indications Indications Multiple actinic or solar keratoses. Superficial basal cell carcinoma when conventional therapy is impractical (5% only); see full labeling. Efudex Cream Dosage and Administration Adult Keratoses: Apply twice daily until eros
Read more

Early symptoms of cancer in males: Common warning signs

-
Image
fluciclovine f 18 :: Article Creator The U.S. Navy Might Be Done With The F/A-18 Super Hornet Fighter Will The U.S. Navy Receive Its Final F/A-18 Super Hornets? - Around the holidays, money can be tight, a fact that the United States Navy has also learned as its negotiations to buy the last batch of Super Hornets are reportedly stalled over the growing price tag. USNI News reported on Tuesday that the contract for the U.S. Navy to purchase the final twenty F/A-18 E/F Super Hornets from aerospace giant Boeing appears to be at a standstill. The Navy continues to work with Boeing on the contract for the 20 congressionally added Super Hornet aircraft. Ongoing contract negotiations cannot be discussed at this time," Capt. Michael Burks, the program manager for the F/A-18 and EA-18G office at Naval Air Systems Command, told USNI News in a statement. Previous estimates put the unit cost of the final batch of aircraft at $55.7 million, and la
Read more

20 Famous Men Who Have Had Prostate Cancer

-
Image
leukemia treatment options :: Article Creator Current And Breakthrough Treatments For Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the immune system. Because it's slow-growing, many people with CLL won't need to start treatment for many years after their diagnosis. Once the cancer begins to grow, there are many available treatment options that can help people achieve remission. This means people can experience long periods of time when there's no sign of cancer in their bodies. The exact treatment option that you'll receive depends on a variety of factors. This includes: whether your CLL is symptomatic the stage of the CLL, based on results of blood tests and a physical exam your age your overall health While there's no cure for CLL yet, breakthroughs in the field are on the horizon. Doctors typically stage CLL using a system called the Rai system. Low
Read more